

**Community Stroke and Rehabilitation Center
10215 W. Broadway
Crown Point, IN 46307**

March 21, 2022

Materials Licensing Branch
USNRC Region III
2443 Warrenville Road

Lisle, IL 60532-4351

RE: Amendment Request for RAM license # 13-35525-01 Community Stroke and Rehab Center

Dear Sir or Madam:


Please add Ajam Samer, MD to our license under 10 CFR 35.200.
Please add Joseph Danavi, MD to our license under 10 CFR 35.200.

Enclosed is a Radioactive Materials License from St. Mary Medical Center, RAM license number 13-03459-03, amendment 41. Dr. Samer and Dr. Danavi are listed on page 3 of 6.

Please contact our Radiation Safety Officer, Santosh Kar, at (219) 836-1600 x31725, or skkar@comhs.org if you have any questions.

I can be reached at (219) 703-1733 or at jpkatz@comhs.org.

Sincerely,



Jacqueline Katz, RT, MBA
Director of Medical Physics
Community Healthcare System.

RECEIVED MAR 24 2022

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p style="text-align: center;">Licensee</p> <p>1. St. Mary Medical Center - Hobart</p>	<p>In accordance with letter dated September 28, 2021,</p>	<p>4. Expiration Date: January 31, 2026</p>
<p>2. 1500 S. Lake Park Ave. Hobart, IN 46342</p>	<p>3. License No.: 13-03459-03 is amended in its entirety to read as follows:</p>	<p>5. Docket No.: 030-31379 Reference No.:</p>

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license	9. Authorized use
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As Needed	A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100.
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As Needed	B. For use in imaging and localization studies permitted by 10 CFR 35.200.
C. Any byproduct material permitted by 10 CFR 35.300	C. Any	C. 500 millicuries total	C. For any use permitted by 10 CFR 35.300.
D. Any byproduct material permitted by 10 CFR 31.11	D. Prepackaged Kits	D. 3 millicuries total	D. For use in in-vitro studies.

RECEIVED MAR 24 2022

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 13-03459-03

Docket or Reference No.:

030-31379

Amendment No. 41

- | | | | |
|---|---|--|---|
| 6. Byproduct, source, and/or special nuclear material | 7. Chemical and/or physical form | 8. Maximum amount that licensee may possess at any one time under this license | 9. Authorized use |
| E. Yttrium-90 permitted by 10 CFR 35.1000 | E. Microspheres (Sirtex, Model SIR-Spheres) | E. 296 millicuries per vial; 2 curies total | E. For use in permanent manual brachytherapy using Sirtex Model SIR-Spheres yttrium-90 microspheres delivery system as permitted by 10 CFR 35.1000. |

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 13-03459-03

Docket or Reference No.:
030-31379

Amendment No. 41

CONDITIONS

10. A. Licensed material listed in Subitem Nos. 6.A. through 6.E. may be used or stored at the licensee's facilities located at 1500 S Lake Park Ave., Hobart, Indiana.
- B. Licensed material listed in Subitem Nos. 6.A. through 6.D. may also be used or stored at the licensee's facilities located at 300 W 61st Ave., Hobart, Indiana.
- C. Licensed material listed in Subitem Nos. 6.A. through 6.B may also be used or stored at the licensee's facilities located at 3545 Arbors Blvd., Portage, Indiana.
- D. Licensed material listed in Subitem Nos. 6.A. through 6.B may also be used or stored at the licensee's facilities located at 3800 St. Mary Drive, Valparaiso, Indiana.

11. The Radiation Safety Officer (RSO) for this license is Santosh K. Kar, M.S.

12. Licensed material shall only be used by, or under the supervision of:

A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.

B. The following individuals are authorized users for the material and medical uses as indicated:

<u>Authorized User (M.D., D.O., etc.)</u>	<u>Material and Use</u>
Samer Ajam, M.D.	10 CFR 35.200
Keith Atassi, M.D.	10 CFR 35.200
Janushi Dalal, M.D.	10 CFR 35.100, 10 CFR 35.200
Joseph Danavi, M.D.	10 CFR 35.200
John W. Gustaitis, Jr., M.D.	10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300
Thomas M. Hoess, M.D.	10 CFR 31.11, 10 CFR 35.100, 10 CFR 35.200
Mikhail Jeha, M.D.	10 CFR 35.100, 10 CFR 35.200
Abdul Kawamleh, M.D.	10 CFR 35.100, 10 CFR 35.200

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 13-03459-03

Docket or Reference No.:

030-31379

Amendment No. 41

Authorized User (M.D., D.O., etc.)

Material and Use

Shawn R. Kenney, M.D.

10 CFR 31.11, 10 CFR 35.100, 10 CFR 35.200

Mohammed M. Khadir, M.D.

10 CFR 35.100, 10 CFR 35.200; 10 CFR 35.1000 (limited to yttrium-90 as SIR-Spheres)

A. Arif Khalil, M.D.

10 CFR 35.200

Akram Knoloki, M.D.

10 CFR 35.100, 10 CFR 35.200

Sorin Lazar, M.D.

10 CFR 35.200

Jonathon T. Lee, M.D.

10 CFR 31.11, 10 CFR 35.100, 10 CFR 35.200

Mary Nicholson, M.D.

10 CFR 35.100, 10 CFR 35.200

Charles-Lauwanga Okoro, D.O.

10 CFR 35.200

Harish Patlolla, M.D.

10 CFR 35.200

Anas Hakam Safadi, M.D.

10 CFR 35.200

Michele Semin, M.D.

10 CFR 35.100, 35.200 and 35.300 (limited to the oral administration of sodium iodide I-131 in quantities of 33 millicuries or less)

Harish Shah, M.D.

10 CFR 35.100, 10 CFR 35.200

Vijah P. Shah, M.D.

10 CFR 35.100, 10 CFR 35.200

Justin Spackey, M.D.

10 CFR 35.100, 10 CFR 35.200

Lingyun Xiong, M.D.

10 CFR 35.300 (limited to the oral administration of sodium iodide I-131 in quantities of 33 millicuries or less)

Ramana Yedavalli, M.D.

10 CFR 35.100, 10 CFR 35.200; 10 CFR 35.1000 (limited to yttrium-90 as SIR-Spheres)

Kais J. Yehyaw, M.D.

10 CFR 35.100, 10 CFR 35.200

Feng Zhang, M.D.

10 CFR 35.100, 10 CFR 35.200; 10 CFR 35.300 (limited to oral administration of sodium iodide I-131 in quantities of 33 millicuries or less)

Jack Ziegler, M.D.

10 CFR 35.200

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 13-03459-03

Docket or Reference No.:

030-31379

Amendment No. 41

13. The licensee shall conduct a physical inventory every 6 months, or at other intervals approved by the U.S. Nuclear Regulatory Commission, to account for all glass microspheres received and possessed under the license. Records of inventories shall be maintained for 3 years from the date of each inventory, and shall include the radionuclides, quantities, manufacturer's name and model numbers, and the date of the inventory.
14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26 and applicable guidance updates for 10 CFR 35.1000 uses. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application dated July 28, 2015 (ML15218A568)
 - B. Letter dated January 6, 2016 (ML16007A729)
 - C. Letter dated January 5, 2017 (ML17018A414)
 - D. Letter dated May 22, 2017 (ML17146B324)
 - E. Letter dated June 20, 2017 (ML17172A121)
 - F. Letter dated September 28, 2017 (ML17276B167)
 - G. Letter dated December 19, 2017 (ML17354A646)

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 13-03459-03

Docket or Reference No.:

030-31379

Amendment No. 41

- H. Letter dated December 19, 2017 (ML17353A894)
- I. Letter dated February 26, 2018 (ML18057A559)
- J. Letter dated September 26, 2019 (ML19270H110)
- K. Letter dated May 11, 2020 (ML20141L681)
- L. Letter dated August 10, 2020 (ML20227A262)
- M. Letter dated September 9, 2020 (ML20260H261)

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: December 16, 2021By: **Laura B. Cender** Digitally signed by Laura B. Cender
Date: 2021.12.16 15:18:06 -06'00'Laura B. Cender
Laura B. Cender
Region 3